期刊文献+

自体外周血造血干细胞移植后造血重建中CD226分子在NK细胞上表达的变化

Expression of CD226 on NK Subsets During Reconstitution of Immune System by Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation
下载PDF
导出
摘要 本文应用双重免疫荧光染色和流式细胞术分析,观察自体外周血造血干细胞移植患者造血重建中,CD226分子在CD56bright和CD56dimNK细胞亚群表达的变化。结果显示,在自体外周血造血干细胞移植造血重建中,于干细胞回输第12天,CD56+NK细胞占外周血淋巴细胞百分率为26.6%,其中CD56bright亚群,占CD56+NK细胞87.3%;CD56+CD226+细胞占CD56+NK细胞92.1%,CD56brightCD226+细胞占CD56+CD226+细胞89.9%。在自体外周血造血干细胞移植造血重建中,CD56bright亚群是NK细胞造血重建最早出现并占优势的一个亚群,CD226分子可能作为一种分化标记主要表达在CD56bright亚群上。 The purpose of this paper was to observe the expression of CD226 on NK subsets during reconstitution of immune system by autologous peripheral blood hematopoietic stem cell transplantation. Double fluorescent staining and flow cytometry analysis were employed to detect the expression of CD226 on CD56^bright and CD56^dim NK subsets during reconstitution of immune system by autologous peripheral blood hematopoietic stem cell transplantation. The results showed that on day 12 after transplantation, the percentage of CD56^+ NK cells in PBMC increased to 26.6%. Among CD56^+ NK cells, the percentage of CD56^bright NK cells was 87.3% and that of CD56^+ CD226^+ subpopulation in CD56^+ NK cells was 92. 1%, and among CD56^+ CD226^+ cells, CD56^bright CD226^+ cells constituted the majority(89. 9%). Our conclusions are that CD226 may be a differentiation marker on CD56^bright NK subset which was the very early appearing and predominant subpopulation of NK cells during the reconstitution of immune system by autologous peripheral blood hematopoietic stem cell transplantation.
出处 《标记免疫分析与临床》 CAS 2005年第3期152-154,134,共4页 Labeled Immunoassays and Clinical Medicine
基金 国家自然科学基金资助项目(NO.39970688) 重点课题资助项目(NO.30030130)
关键词 CD226 NK细胞 亚群 干细胞移植 CD226 NK cell Subset Stem cell transplantation
  • 相关文献

参考文献4

二级参考文献24

  • 1[1]Philip Th, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma[J]. N Engl J Med, 1995,333(23):1540~1546
  • 2[2]Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia [J]. N Engl J Med, 1995,332(3):217~224
  • 3[3]Attal M, Harousseau JL, Stoppa AM, et al. A prospective,randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J]. N Engl J Med,1996,335(1):91~97
  • 4[4]Avigan D, Wu Z, Joyce R, et al. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer [J]. Bone Marrow Transplant, 2000,26(2):169~177
  • 5[5]Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogenetic marrow transplantation compared with blood stem cell transplantation[J]. Blood, 2001,97(11):3380~3385
  • 6[6]Raaphorst FM. Bone marrow transplantation, Fetal B-cell repertoire development, and the mechanism of immune reconstitution[J]. Blood, 1998,92(12):4873~4881
  • 7[7]Antin JH. Long term care after hematopoieti-cell transplantation in adults[J]. N Engl J Med, 2002,347(1):36~47
  • 8[8]Storek J, Joseph A, Espino G, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation[J]. Blood, 2001,98(13):3505~3515
  • 9[9]Bomberger C, Jairam MS, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACSsorted CD34+ hematopoietic progenitors[J]. Blood, 1998,91(7):2588~2600
  • 10[10]Cérard Socie. Long-term immune reconstitution after marrow transplantation[J]. Blood, 2001,98(13):3503~3511

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部